In general, the risk of hypoglycemia is greater when one compares insulin therapy with the insulin secretagogues (sulphonylureas, mitiglinides, diethyl-dipeptidase 4 inhibitors, or GLP-1 agonists) and therefore the risk of cognitive compromise will always be greater when insulin is compared to other antidiabetic agents. The gene discussed is INS; the disease is Hypoglycemia.